A Study of LY4515100 in Healthy Participants
ConditionHealthy
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEli Lilly and Company
About this trial
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 30 days and will include six overnight stays.
Eligibility criteria
Qualifiers
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
Have a body mass index within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
Individuals of childbearing potential (IOCBP) are excluded from this trial.
Individuals not of childbearing potential (INOCBP) may participate in this trial.
Disqualifiers
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
Participants with an estimated glomerular filtration rate <90 mL/min/1.73 m2.
Trial design
Treatments tested in this trial
- LY4515100 via SAD
- LY4515100 via MAD
Treatment groups
40 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov